KR940703840A - 치환 벤즈이미다졸, 그의 제조 방법 및 용도(substituted benzimidazoles, process for their preparation as well as their use) - Google Patents

치환 벤즈이미다졸, 그의 제조 방법 및 용도(substituted benzimidazoles, process for their preparation as well as their use)

Info

Publication number
KR940703840A
KR940703840A KR1019940702131A KR19940702131A KR940703840A KR 940703840 A KR940703840 A KR 940703840A KR 1019940702131 A KR1019940702131 A KR 1019940702131A KR 19940702131 A KR19940702131 A KR 19940702131A KR 940703840 A KR940703840 A KR 940703840A
Authority
KR
South Korea
Prior art keywords
methyl
compound
sulfinyl
pyridinyl
dimethoxy
Prior art date
Application number
KR1019940702131A
Other languages
English (en)
Inventor
카알 비외른 크리스터 홀스타인
군넬 엘리자베드 순덴
Original Assignee
클래스 빌헬름슨
악티에볼라게트 아스트라
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 클래스 빌헬름슨, 악티에볼라게트 아스트라 filed Critical 클래스 빌헬름슨
Publication of KR940703840A publication Critical patent/KR940703840A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명은 하기 일반식(Ⅰ)의 신규 화합물, 상기 화합물의 제조 방법, 활성 성분으로서 상기 화합물을 함유하는 제약 조성물, 및 약제에서의 그의 용도에 관한 것이다.
상기 식중, R1및 R2는 각각 상이한 것으로서, 메틸, -C(O)-CH3또는 -C(O)-OCH3이고, R1또는 R2중 하나는 항상 메틸이며, M은 생리학적으로 허용가능한 카운터 양이온이다.

Description

치환 벤즈이미다졸, 그의 제조 방법 및 용도(SUBSTITUTED BENZIMIDAZOLES, PROCESS FOR THEIR PREPARATION AS WELL AS THEIR USE)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (19)

  1. 하기 일반식(Ⅰ)의 화합물.
    상기 식중, R1및 R2는 각각 상이한 것으로서, 메틸, -C(O)-CH3또는 -C(O)-OCH3이고, R1또는 R2중 하나는 항상 메틸이며, M은 생리학적으로 허용가능한 카운터 양이온이다.
  2. 제1항에 있어서, M이 Na, K, Ag 또는 트리알킬암모늄인 화합물.
  3. 제1항에 있어서, 인산, [5-아세틸-6-메틸-2[[3,4-디메톡시-2-피리디닐)메틸]술피닐]-1H-벤즈이미다졸-1-일]메틸 에스테르, 이나트륨염 및 인산, [6-아세틸-5-메틸-2-[[3,4-디메톡시-2-피리디닐)메틸]술피닐]-1H-벤즈이미다졸-1-일]메틸 에스테르, 이나트륨염의 혼합물인 일반식(Ⅰ)의 화합물.
  4. 제1항에 있어서, 인산, [5-카르보메톡시-6-메틸-2[[3,4-디메톡시-2-피리디닐)메틸]술피닐]-1H-벤즈이미다졸-1-일]메틸 에스테르, 이나트륨염 및 인산, [6-카르보메톡시-5-메틸-2-[[3,4-디메톡시-2-피리디닐)메틸]술피닐]-1H-벤즈이미다졸-1-일]메틸 에스테르, 이나트륨염의 혼합물인 일반식(Ⅰ)의 화합물.
  5. 제1항에 있어서, 인산, [5-아세틸-6-메틸-2-[[3,4-디메톡시-2-피리디닐)메틸]술피닐]-1H-벤즈이미다졸-1-일]메틸 에스테르, 이나트륨염인 화합물.
  6. 제1항에 있어서, 인산, [6-아세틸-5-메틸-2[[3,4-디메톡시-2-피리디닐)메틸]술피닐]-1H-벤즈이미다졸-1-일]메틸 에스테르, 이나트륨염인 화합물.
  7. 제1항에 있어서, 인산, [5-카르보메톡시-6-메틸-2-[[3,4-디메톡시-2-피리디닐)메틸]술피닐]-1H-벤즈이미다졸-1-일]메틸 에스테르, 이나트륨염인 화합물.
  8. 제1항에 있어서, 인산, [6-카르보메톡시-5-메틸-2-[[3,4-디메톡시-2-피리디닐)메틸]술피닐]-1H-벤즈이미다졸-1-일]메틸 에스테르, 이나트륨염인 화합물.
  9. 제1항에 따른 화합물을 활성 성분으로서 함유하는 제약 조성물.
  10. 치료용의 제1항에 따른 화합물.
  11. 인체를 포함한 포유류에서의 위산 분비 억제용의 제1항에 따른 화합물.
  12. 인체를 포함한 포유류에서의 위장의 염증성 질환 치료용의 제1항에 따른 화합물.
  13. 제1항에 따른 화합물을 인체를 포함한 포유류에게 투여함으로써 위산의 분비를 억제하는 방법.
  14. 제1항에 따른 화합물을 인체를 포함한 포유류에게 투여함으로써 위장의 염증성 질환을 치료하는 방법.
  15. 인체를 포함한 포유류에서 위산의 분비를 억제하기 위한 의약 제조에 있어서, 제1항에 따른 화합물의 용도.
  16. 인체를 포함한 포유류에서 위장의 염증성 질환을 치료하기 위한 의약 제조에 있어서 제1항에 따른 화합물의 용도.
  17. a) 하기 일반식(Ⅱ)의 화합물을 하기 일반식(Ⅲ)의 화합물과 반응시키거나 또는 b) 하기 일반식(Ⅳ)의 화합물을 산화시키는 것으로 이루어진 제1항에 따른 일반식(Ⅰ)의 화합물의 제조 방법.
    상기 식중, R1, R2, 및 M은 일반식(Ⅰ)에서 정의된 바와 같고, Z는 Cl, Br 또는 Ⅰ와 같은 할로겐 또는 기능적으로 등가인 기이고, Q는 Na+, K+, Ag+또는 트리알킬암모늄과 같은 카운터 이온이다.
  18. 하기 일반식(Ⅱ)의 화합물.
    상기 식중, R1, R2는 일반식(Ⅰ)에서 정의된 바와 같고, Z는 Cl, Br 또는 Ⅰ와 같은 할로겐 또는 기능적으로 등가인 것이다.
  19. 제18항에 있어서, R1및 R2가 상기에서 정의된 바와 같고, Z가 Cl 또는 OH인 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940702131A 1991-12-19 1992-12-08 치환 벤즈이미다졸, 그의 제조 방법 및 용도(substituted benzimidazoles, process for their preparation as well as their use) KR940703840A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9103776-2 1991-12-19
SE9103776A SE9103776D0 (sv) 1991-12-19 1991-12-19 New compounds
PCT/SE1992/000844 WO1993012124A1 (en) 1991-12-19 1992-12-08 Substituted benzimidazoles, process for their preparation as well as their use

Publications (1)

Publication Number Publication Date
KR940703840A true KR940703840A (ko) 1994-12-12

Family

ID=20384667

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702131A KR940703840A (ko) 1991-12-19 1992-12-08 치환 벤즈이미다졸, 그의 제조 방법 및 용도(substituted benzimidazoles, process for their preparation as well as their use)

Country Status (25)

Country Link
EP (1) EP0628049A1 (ko)
JP (1) JPH07502503A (ko)
KR (1) KR940703840A (ko)
CN (1) CN1031827C (ko)
AP (1) AP397A (ko)
AU (1) AU665043B2 (ko)
CA (1) CA2124689A1 (ko)
CZ (1) CZ146794A3 (ko)
FI (1) FI942912A0 (ko)
HR (1) HRP921400A2 (ko)
HU (1) HUT68270A (ko)
IL (1) IL104025A0 (ko)
IS (2) IS4079A (ko)
MA (1) MA22746A1 (ko)
MX (1) MX9207269A (ko)
NO (1) NO942230L (ko)
NZ (1) NZ246220A (ko)
SE (1) SE9103776D0 (ko)
SI (1) SI9200402A (ko)
SK (1) SK73594A3 (ko)
TN (1) TNSN92115A1 (ko)
TW (1) TW224100B (ko)
WO (1) WO1993012124A1 (ko)
YU (1) YU101692A (ko)
ZA (1) ZA928836B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19645974C1 (de) * 1996-11-07 1998-08-13 Andreas Johannes Kesel (Z)-5-[[3-Hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methylen]-2-thioxo-4- thiazolidinon, Verfahren zu dessen Herstellung und Verwendung
ATE261730T1 (de) * 1997-12-31 2004-04-15 Univ Kansas Wasserlösliche medikamentenvorstufen tertiärer amine enthaltender medikamente und verfahren zu ihrer herstellung
ATE467637T1 (de) 2005-07-28 2010-05-15 Intervet Int Bv Neue benzimidazol(thio)carbamate mit antiparasitischer wirkung und ihre synthese
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
KR101403135B1 (ko) 2006-06-14 2014-06-19 인터벳 인터내셔널 비.브이. 벤지미다졸 카르바메이트 및 폴리솔베이트를 포함하는 현탁물
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8513287B2 (en) * 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
MX365051B (es) 2014-11-26 2019-05-09 Univ Mexico Nac Autonoma Nuevos compuestos hidrosolubles derivados del bencimidazol, utiles para el tratamiento de la fasciolosis.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ234564A (en) * 1986-11-21 1991-04-26 Haessle Ab 1-substituted benzimidazoles and pharmaceutical compositions
SE8801907D0 (sv) * 1988-05-20 1988-05-20 Haessle Ab Novel pharmacological compounds
SE9002206D0 (sv) * 1990-06-20 1990-06-20 Haessle Ab New compounds
ATE184602T1 (de) * 1990-06-20 1999-10-15 Astra Ab Dialkoxypyridinylbenzimidazolderivate, verfahren zur herstellung und ihre pharmazeutische verwendung

Also Published As

Publication number Publication date
NZ246220A (en) 1996-02-27
CN1073446A (zh) 1993-06-23
EP0628049A1 (en) 1994-12-14
FI942912A (fi) 1994-06-17
AP397A (en) 1995-08-14
HUT68270A (en) 1995-06-28
NO942230D0 (no) 1994-06-14
ZA928836B (en) 1993-07-05
IS4079A (is) 1993-06-20
SK73594A3 (en) 1995-02-08
CN1031827C (zh) 1996-05-22
HRP921400A2 (en) 1994-08-31
MX9207269A (es) 1993-06-01
NO942230L (no) 1994-06-14
YU101692A (sh) 1995-10-03
CZ146794A3 (en) 1996-02-14
WO1993012124A1 (en) 1993-06-24
AU3175293A (en) 1993-07-19
JPH07502503A (ja) 1995-03-16
SE9103776D0 (sv) 1991-12-19
TW224100B (ko) 1994-05-21
IS3960A (is) 1993-06-20
AU665043B2 (en) 1995-12-14
FI942912A0 (fi) 1994-06-17
HU9401840D0 (en) 1994-09-28
SI9200402A (en) 1993-06-30
IL104025A0 (en) 1993-05-13
TNSN92115A1 (fr) 1993-06-08
MA22746A1 (fr) 1993-07-01
CA2124689A1 (en) 1993-06-24
AP9200463A0 (en) 1993-01-31

Similar Documents

Publication Publication Date Title
KR930000861B1 (ko) 오메프라졸 직장투여 조성물
EP0259468B1 (de) Cyclodextrinclathrate von carbacyclinderivaten und ihre verwendung als arzneimittel
CA2083606A1 (en) Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use
CA2412795A1 (en) Improved liposomal camptothecins and uses thereof
KR890011592A (ko) 기관내 허혈병의 치료용 조성물
HK1089749A1 (en) Use of a pharmaceutical composition containing a para-aminophenyl acetic acid derivative for treating inflammatory conditions of the gastrointestinal tract
KR880005092A (ko) 항궤양제로서 유효한 벤즈이미다졸의 신규 유도체
KR20000049281A (ko) 히알루론산과 국소 마취제의 염으로 이루어진 약제
FR2387941A1 (fr) Homologue de la somatostatine, ses intermediaires de preparation, et son utilisation comme medicament
EP0368640A3 (en) Heterocyclic compounds
PL209943B1 (pl) Zastosowanie moksifloksacyny stanowiącej kwas 1-cyklopropylo-6-fluoro-1,4-dihydro-8-metoksy-7-[(4aS,7aS)-oktahydro-6H-pirolo [3,4-b]pirydyn-6-ylo]-4-okso-3-chinolino-karboksylowy
EP0371559A3 (en) Use of benzimidazoles in the treatment of epithelial disorders
DE2360797C2 (de) Pharmazeutische Präparate
KR940703840A (ko) 치환 벤즈이미다졸, 그의 제조 방법 및 용도(substituted benzimidazoles, process for their preparation as well as their use)
GR3019917T3 (en) Benzimidazole derivatives as antimicrobal agent against campylobacter pylon
SE8406201L (sv) Penicillansyraderivat
KR910700248A (ko) 위산 분비 억제 효과를 갖는 화합물 및 그의 제조 방법
DE2611183A1 (de) Stabile dosierungsform von prostaglandinartigen verbindungen
US5260287A (en) Polyphosphorylated organic compounds: compositions useful in protecting biological tissues
KR0147855B1 (ko) 골형성 촉진제
EP0069380A1 (en) 11-Deoxoglycyrrhetinic acid hydrogen maleate, process for its production, and its use as a medicine
EP0324745B1 (de) Prostacyclinderivate enthaltende mittel für die topische anwendung
IE61381B1 (en) Topically applied gold organic complex
US3852454A (en) Treatment of rheumatoid arthritis
US3026247A (en) Pharmaceutical preparation

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid